Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma.
The bronchodilating effects of atrial natriuretic factor (ANF) were compared to effects of salbutamol in a double-blind, placebo-controlled, crossover study in eight subjects with asthma and with airflow limitation. ANF was infused intravenously (0.1 microgram/kg/min during 30 minutes) and caused a short-lasting significant (p less than 0.012) bronchodilation in all patients similar in intensity to intravenous salbutamol (0.13 microgram/kg/min). The duration of the effect of the beta 2-agonist, however, was longer. No severe side effects were noted with ANF infusion. ANF may play a role in the modulation of the bronchial tone in humans, but its usefulness in the treatment of asthma remains to be determined.
Chanez
P
P
Clinique des Maladies Respiratoires, Hôpital de l'Aiguelongue, Montpellier, France.
Mann
C
C
Bousquet
J
J
Chabrier
P E
PE
Godard
P
P
Braquet
P
P
Michel
F B
FB
D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000627:therapeutic use*; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans
D009320:Atrial Natriuretic Factor